Q-omics provides the consensus-scored FOXN1 profile across patient tissues and cancer cell-line models. FOXN1 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, FOXN1 is differentially expressed in 11, with the highest sampling consensus in THCA. Additionally, FOXN1 RNA expression shows 11,344 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight HNSC, THCA, and THYM as cancer lineages where FOXN1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for FOXN1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes FOXN1 survival associations across molecular data types. FOXN1 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (5) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible FOXN1 RNA expression–survival associations across cancer types. High FOXN1 expression shows unfavorable associations in KIRC, but favorable associations in HNSC, LUSC, CESC, MESO and BRCA. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for FOXN1 RNA expression.
This table summarizes FOXN1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 3. The strongest signals are observed in THCA for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for FOXN1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. FOXN1 shows lower tumor expression in THCA, KIRC and KICH and higher tumor expression in LUSC, CHOL and HNSC. The THCA box plot shows higher FOXN1 RNA expression in normal versus tumor tissue (log2 FC = −0.630, t-test p < 0.001).
This table shows molecular features associated with FOXN1 in patient tissues and cancer cell lines. In patient samples, FOXN1 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, FOXN1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in URINARY_TRACT, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUSC and LUNG_NSCLC_LUAD.
